BioNTech and CEPI Announce Partnership to Advance mRNA Mpox

BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the development of

Related Keywords

Norway , United Kingdom , Kigali , W09 , Rwanda , Germany , Fosun Pharma , Richard Hatchett , Kate Kelland , Ugur Sahin , Roche Group , Genentech , United Kingdom Health Security Agency , Regulatory Agency , Days Mission , Pfizer , Coalition For Epidemic Preparedness Innovations , World Health Organization Foundation , Days Mission To End Pandemics , Exchange Commission , Epidemic Preparedness Innovations , Chief Executive Officer , New Technologies , Private Securities Litigation Reform Act , Ebola Virus Disease , Middle East Respiratory Syndrome , Rift Valley Fever , End Pandemics , Scientific Writer Kate Kelland , United Kingdom Medicines ,